A Phase III study of 814 patients with type 2 diabetes indicated that 67% of those who used dapagliflozin as an add-on to metformin saw reductions in both weight and HbA1C levels at 52 weeks, compared with 21% of those who used glipizide as an add-on treatment. The findings were presented at the American Diabetes Association's 73rd Scientific Sessions.

Related Summaries